Data from EMC - Curated by Toby Galbraith - Last updated 02 May 2017

Licensing authority

EMA (European Medicines Agency)

Indication(s)

Treatment of osteoporosis
- in post-menopausal women
- in adult men
at increased risk of fracture, including those with a recent low-trauma hip fracture.

Treatment of osteoporosis associated with long-term systemic glucocorticoid therapy
- in post-menopausal women
- in adult men
at increased risk of fracture.

Treatment of Paget’s disease of the bone in adults.

Full Prescribing information

Learning Zones

An epgonline.org Learning Zone (LZ) is an area of the site dedicated to providing detailed self-directed medical education about a disease, condition or procedure.

Acute and Advanced Heart Failure

What are the most effective treatments for acute heart failure? Can you define advanced heart failure? Discover here...

Visit Acute and Advanced Heart Failure

Type 2 Diabetes

View the latest epidemiology data, patient perspectives, ADA and EASD recommendations, treatment options and more

Visit Type 2 Diabetes

More information

Category Value
Agency product number EMEA/H/C/000595
Orphan designation No
Date First Approved 15-04-2005
Type Medicinal product subject to restricted medical prescription
Marketing authorisation holder Novartis Europharm Limited
Warnings

European Medicines Agency concludes class review of bisphosphonates and atypical fractures (European Medicines Agency - Press Release 15/04/2011)

Rare atypical fr

Related Content